 PALO ALTO, Calif. , Sept. 1, 2021 PRNewswire -- Kodiak Sciences Inc. Nasdaq: KOD, a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high-prevalence retinal diseases, today announced new seven-year performance stock option awards under a Long-Term Performance Incentive Plan LTPIP for named executive officers NEOs as well as other eligible Kodiak employees, subject to stockholder approval of the LTPIP at a special meeting expected to be held in October. 